Johnson & Johnson $JNJ Shares Sold by Rockland Trust Co.

Key Points

• Rockland Trust Co. reduced its Johnson & Johnson stake by 5.3% in the third quarter, selling 4,125 shares and retaining 74,352 shares valued at approximately $19.7 million. Institutional investors and hedge funds collectively own 69.55% of JNJ.
• Johnson & Johnson exceeded quarterly expectations with $2.90 in EPS and $25.31 billion in revenue, while revenue grew 6.6% year over year. The company set fiscal 2026 EPS guidance at $11.60–$11.75 and declared a quarterly dividend of $1.34 per share.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $275.87, although company insiders sold 87,569 shares worth approximately $23.1 million over the past 90 days.

Rockland Trust Co. reduced its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 74,352 shares of the company's stock after selling 4,125 shares during the period. Rockland Trust Co.'s holdings in Johnson & Johnson were worth $19,684,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Outlook Capital Management LLC purchased a new position in Johnson & Johnson during the second quarter valued at approximately $28,000. Matrix Trust Co boosted its stake in shares of Johnson & Johnson by 56.2% during the 2nd quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after acquiring an additional 54 shares in the last quarter. Hyposwiss Advisors SA acquired a new position in shares of Johnson & Johnson during the 4th quarter valued at about $42,000. Montgomery Financial Services LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at approximately $43,000. Finally, Polaris Financial Partners bought a new stake in Johnson & Johnson during the third quarter worth approximately $56,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock traded down $2.00 during trading on Monday, reaching $254.03. The company's stock had a trading volume of 3,741,572 shares, compared to its average volume of 7,973,521. The stock has a 50-day moving average price of $266.37 and a two-hundred day moving average price of $248.40. The stock has a market capitalization of $612.19 billion, a P/E ratio of 29.43, a price-to-earnings-growth ratio of 2.52 and a beta of 0.21. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a one year low of $182.94 and a one year high of $281.07.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts' consensus estimates of $2.84 by $0.06. The firm had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company's revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.54 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson's dividend payout ratio is 62.11%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer Taubert sold 15,000 shares of the company's stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction on Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 87,569 shares of company stock worth $23,064,544. Company insiders own 0.16% of the company's stock.

Analyst Ratings Changes

JNJ has been the topic of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on shares of Johnson & Johnson from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Tuesday, September 29th. Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 16th. Raymond James Financial set a $280.00 target price on Johnson & Johnson in a research report on Monday, August 3rd. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $284.00 to $294.00 and gave the company an "overweight" rating in a research report on Thursday, July 16th. Finally, HSBC increased their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the stock a "buy" rating in a research report on Thursday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $275.87.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.